MMP9 and breast carcinoma: ESMC treatment could not only reduce the protein expression but also repress the enzymatic activity of MMP-2 and MMP-9, which suggests that ESMC's anti-invasive action was mediated by diminishing the ability of breast cancer cells to degrade the components of ECM by modulating MMP-2 and MMP-9 expression and activity [26].